Gilead Acquires Arcellx for $7.8 Billion to Boost CAR-T Therapy
Gilead Sciences, a prominent player in the biopharmaceutical industry, has announced its acquisition of Arcellx for $7.8 billion. This strategic move comes as Gilead prepares for the anticipated approval and…